Haduvio™: Relief is Possible
We are developing Haduvio™ (nalbuphine ER) unlocking new market opportunities and the potential to significantly improve the quality of life of patients suffering from the serious symptoms associated with chronic neurologically mediated conditions.
Passionate about Progress
Backed by expert scientific and medical advisors and dedicated to our investors, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building companies of exceptional value.
Passionate about Progress
Backed by expert scientific and medical advisors and dedicated to our investors, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building companies of exceptional value.
A New Hope for Patients with Chronic and Serious Neurologically Mediated Conditions
We are developing Haduvio™ as an oral treatment for a broad range of chronic conditions for which patients have few, if any, treatment options. With its unique dual mechanism of action, Haduvio™ has the potential to significantly improve the quality of life of patients.
Committed to Excellence in Pharmaceutical Development and Bringing Solutions to Patients
news
10/21/2020
Restart of Phase 2 Clinical Trial of Haduvio for Chronic Cough in Patients with IPF Phase 2b/3 PRISM Trial of Haduvio for Severe Pruritus in Patients with Prurigo Nodularis Reaches 50% Enrollment Milestone NEW HAVEN, Conn. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc.
10/13/2020
Expands Management Team to Support Clinical Development and Commercial Strategy of Haduvio™ in Multiple Late Stage Programs NEW HAVEN, Conn. , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and
09/09/2020
NEW HAVEN, Conn. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management
